13F Holdings
中文EN

CRDL Cardiol Therapeutics Inc. IFRS Annual reports only

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1702123 · Reporting currency CAD · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY7.8%
TTM EPS YoY23.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-158.8%
ROA-121.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets24.3%
Debt / equity0.00x
Current ratio4.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-35.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: CAD FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue————78,760
R&D expense14.02M14.01M14.22M18.96M10.87M
SG&A expense20.30M26.26M15.56M22.37M27.87M
Operating income-34.32M-40.28M-29.79M-41.34M-38.66M
Income tax———00
Net income-33.82M-36.68M-28.13M-30.93M-31.64M
EPS (basic)-0.39-0.51-0.44-0.49-0.73
EPS (diluted)-0.39-0.51-0.44-0.49-0.73
Weighted avg. shares (diluted)86.99M71.57M64.46M62.51M43.22M
Balance sheet
Cash & equivalents21.42M30.58M34.93M59.47M83.90M
Receivables55,727100,366142,745209,92365,739
Current assets23.50M31.67M36.15M61.44M87.14M
PP&E, netmay include right-of-use assets (IFRS)118,093195,592337,058295,738356,493
Intangibles——210,358294,802379,246
Total assets23.62M31.86M36.70M62.03M87.88M
Current liabilities5.66M7.01M8.30M9.80M11.57M
Total liabilities5.74M7.14M8.45M9.83M11.64M
Shareholders' equity17.88M24.73M28.25M52.20M76.24M
Cash flow statement
Operating cash flow-23.85M-25.06M-25.18M-27.22M-23.54M
Capital expenditure24,48421,29064,31274,70912,916
Free cash flow-23.88M-25.08M-25.24M-27.30M-23.55M
Investing cash flow-24,484-21,290-64,312-74,709-12,916
Financing cash flow15.54M18.84M-55,376-53,93493.44M
Stock-based compensation10.70M14.28M4.16M5.01M8.50M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.